French regulatory agency allows Nanobiotix to begin NBTXR3 Phase I trial
In the trial, NBTXR3 will be given to the patients before surgery by a single intra-tumoral injection followed by standard radiotherapy procedure. The primary endpoints of the clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.